Interferons in Systemic Lupus Erythematosus
Skewing of type I interferon (IFN) production and responses is a hallmark of systemic lupus erythematosus (SLE). Genetic and environmental contributions to IFN production lead to aberrant innate and adaptive immune activation even before clinical development of disease. Basic and translational research in this arena continues to identify contributions of IFNs to disease pathogenesis, and several promising therapeutic options for targeting of type I IFNs and their signaling pathways are in development for treatment of SLE patients.
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Sirisha Sirobhushanam, Stephanie Lazar, J. Michelle Kahlenberg Source Type: research